HC Advisors’s Fulcrum Therapeutics FULC Stock Holding History

HC Advisors’s Portfolio FULC Stock Details FULC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-11,800	Closed	-$216K	–	80
2020 Q2	$216K	Buy	+11,800	New	+$186K	0.18%	73

Other funds holding FULC

TGI

TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return

TGI

TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

HC Advisors's FULC Position: Q3 2020 in Review

HC Advisors sold out of Fulcrum Therapeutics (FULC) in Q3 2020, closing a stake of 11,800 shares — an estimated $216K sold.

HC Advisors first reported a position in FULC in Q2 2020 and held it in 1 quarter. The position peaked at $216K in Q2 2020. 55 funds tracked by Wall St. Rank hold FULC as of Q3 2020.

HC Advisors reported no remaining Fulcrum Therapeutics position as of Q3 2020 after selling out during the quarter.
HC Advisors sold 11,800 Fulcrum Therapeutics shares in Q3 2020, an estimated $216K.
HC Advisors first reported a position in Fulcrum Therapeutics in Q2 2020 and held it in 1 quarter.
HC Advisors's Fulcrum Therapeutics position peaked at $216K in Q2 2020.
55 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q3 2020.

Based on HC Advisors's 13F filing for Q3 2020, filed 4 Nov 2020.